Heterozygous mutations in GATA3, mostly frameshifts, occur in approximately 15% of primary ER+ human breast cancers, suggesting that Gata3 may function as a haploinsufficient tumor suppressor for luminal breast cancers. Here, GATA3 is linked to neoplasm.